Key result
Hydroxychloroquine shows ~80% 6-year retention in SLE patients to prevent cardiometabolic and thrombotic complications.
Cohort
Answers are grounded in this paper and cite their sources.
Hydroxychloroquine is used by 35% of SLE patients enrolled in the Baltimore Lupus Cohort. Eighty per cent of patients who took hydroxychloroquine at cohort entry remain on it six years later. In addition to its role for disease manifestations of lupus, hydroxychloroquine may be indicated for the prevention of disease or treatment-induced complications, including hyperlipidemia, diabetes mellitus, liver function test elevation and thrombosis.
No takes yet. Share an insight, caveat, or question.
Michelle Petri (1996) conducted a cohort in Systemic lupus erythematosus (SLE). Hydroxychloroquine was evaluated on Prevention of disease or treatment-induced complications, including hyperlipidemia, diabetes mellitus, liver function test elevation, and thrombosis. Hydroxychloroquine was used by 35% of SLE patients in the Baltimore Lupus Cohort, with 80% remaining on therapy at 6 years to help prevent lipid, glucose, and thrombotic complications.
Synapse has enriched 10 related papers. Consider them for comparative context: